Meyer Turku has delivered Royal Caribbean's newest Icon-class ship, Legend of the Seas, marking the third vessel in the series. The ship will debut in July with Western Mediterranean cruises before heading to Florida in November for Caribbean itineraries. This delivery is part of a long-term agreement between Royal Caribbean Group and Meyer Turku, securing shipbuilding capacity through 2036.

Navan, Inc.'s average 12-month stock price target has been increased to $24.27 from $23.93, suggesting a 16% potential upside from its June 10 closing price. This revised target, based on estimates from 15 analysts, has a range of $18 to $31 per share. The consensus analyst rating remains "Buy," with all covering analysts recommending a buy.

Analysts have raised the average 12-month price target for Liberty Global Ltd. (LBTYA) stock to $16.42, up from $16.06. This new target implies a potential upside of approximately 44% from its June 10 closing price. The consensus rating from 10 analysts remains "Buy," with a breakdown of 4 Buys, 5 Holds, and 1 Sell.

Procter & Gamble is experiencing an exodus of top female executives in 2026, with Fatima Francisco, global head of paper products, announced to retire in September. This marks the third departure of a high-ranking woman from the company. Francisco, who leads a unit generating 24% of P&G's sales, was considered a potential candidate for the company's first female CEO.

Industrial Logistics Properties Trust (ILPT) has appointed Elena B. Poptodorova, a career diplomat and former Bulgarian ambassador, to its Board of Trustees. This unexpected move signals a strategic shift for ILPT, emphasizing the importance of geopolitical expertise in managing risks within global logistics and fractured supply chains. The appointment suggests that understanding international affairs and trade policy is becoming as crucial for asset value protection as traditional property and financial expertise, especially given ILPT's strong financial position after recent debt refinancing and robust leasing activity.

Brown & Brown (NYSE:BRO) has appointed Corey Lewis as Global Head of Tax Insurance to expand its transactional tax solutions for private equity and M&A clients, reflecting increasing complexity in this sector. This strategic move, supported by expanded credit facilities, aims to deepen client relationships and compete with other global brokers. Investors should monitor the build-out of Lewis's team and potential financial impacts, while noting the company's historical earnings growth.

This article discusses the debate among readers about the value of waiting in line for Costco's cheaper gas, weighing the savings against the time commitment. It also touches on concerns about gas station ads and briefly mentions other news, including skepticism around a "solid-state" battery claim and a collaboration between Porsche and Pixar for "Toy Story"-themed cars. Readers share various strategies for fuel purchases and express their frustrations with pump-side video advertisements.

This article analyzes Ishares Ibonds Dec 2054 Term Treasury Etf (IBGK), indicating a neutral sentiment across all time horizons with support being tested. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 8.1:1 risk-reward setup, targeting a 2.5% gain versus 0.3% risk.

HSBC Holdings PLC shares dropped 3.6% to $86.16, making it significantly overvalued by 60.5% compared to its GF Value™ of $53.68. The company's GF Score™ of 62/100, while "Above Average," highlights weaknesses in financial strength, profitability, and valuation. Insider selling of $0.4 million over the last three months further suggests a lack of confidence in the stock's current valuation.

Humacyte Inc. has announced an underwritten public offering of its common stock, with underwriters having a 30-day option to purchase an additional 15% of shares. The biotechnology company plans to use the proceeds to fund the commercialization of Symvess, its FDA-approved product, support a Biologics License Application supplement for hemodialysis, advance pipeline product candidates, and for general corporate purposes. This follows a 45% year-to-date surge in its stock, positive Phase 3 results for its dialysis access product, and increased price targets from analysts.